7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features

      research-article
      1 , 16 , 2 , 3 , 3 , 4 , 5 , 2 , 2 , 3 , 6 , 7 , 8 , 7 , 2 , 2 , 2 , 5 , 2 , 1 , 1 , 1 , 3 , 3 , 3 , 2 , 3 , 8 , 8 , 4 , 9 , 9 , 9 , 3 , 5 , 8 , 7 , 10 , 2 , 11 , 2 , 12 , 12 , 3 , 7 , 2 , 13 , 13 , 14 , 4 , 2 , 15 , 2 , 9 , 1 , , 3 , 12 , , 1 , 3 , , 2 , 17 ,
      Nature Communications
      Nature Publishing Group UK

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Racial/ethnic disparities in breast cancer mortality continue to widen but genomic studies rarely interrogate breast cancer in diverse populations. Through genome, exome, and RNA sequencing, we examined the molecular features of breast cancers using 194 patients from Nigeria and 1037 patients from The Cancer Genome Atlas (TCGA). Relative to Black and White cohorts in TCGA, Nigerian HR + /HER2 − tumors are characterized by increased homologous recombination deficiency signature, pervasive TP53 mutations, and greater structural variation—indicating aggressive biology. GATA3 mutations are also more frequent in Nigerians regardless of subtype. Higher proportions of APOBEC-mediated substitutions strongly associate with PIK3CA and CDH1 mutations, which are underrepresented in Nigerians and Blacks. PLK2, KDM6A, and B2M are also identified as previously unreported significantly mutated genes in breast cancer. This dataset provides novel insights into potential molecular mechanisms underlying outcome disparities and lay a foundation for deployment of precision therapeutics in underserved populations.

          Abstract

          Research on racial and ethnic influence on breast cancer mortality is stymied by a lack of genomic studies in diverse populations. Here, the authors genomically interrogate 194 Nigerian breast cancers, unveiling molecular features that could explain the high mortality rate from breast cancer in an indigenous African population.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Genetic landscape of esophageal squamous cell carcinoma.

          Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers. We performed exome sequencing on 113 tumor-normal pairs, yielding a mean of 82 non-silent mutations per tumor, and 8 cell lines. The mutational profile of ESCC closely resembles those of squamous cell carcinomas of other tissues but differs from that of esophageal adenocarcinoma. Genes involved in cell cycle and apoptosis regulation were mutated in 99% of cases by somatic alterations of TP53 (93%), CCND1 (33%), CDKN2A (20%), NFE2L2 (10%) and RB1 (9%). Histone modifier genes were frequently mutated, including KMT2D (also called MLL2; 19%), KMT2C (MLL3; 6%), KDM6A (7%), EP300 (10%) and CREBBP (6%). EP300 mutations were associated with poor survival. The Hippo and Notch pathways were dysregulated by mutations in FAT1, FAT2, FAT3 or FAT4 (27%) or AJUBA (JUB; 7%) and NOTCH1, NOTCH2 or NOTCH3 (22%) or FBXW7 (5%), respectively. These results define the mutational landscape of ESCC and highlight mutations in epigenetic modulators with prognostic and potentially therapeutic implications.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer

            Paz Polak, Jaegil Kim, Lior Z. Braunstein and colleagues have identified patterns of genome-wide mutation in certain breast cancers that can be used to identify those with DNA-repair deficiencies that make the tumor more likely to respond to therapies based on PARP inhibitors or platinum. In contrast, oncogenic mutations in several other DNA-repair genes do not generate these patterns.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Oncotator: cancer variant annotation tool.

              Oncotator is a tool for annotating genomic point mutations and short nucleotide insertions/deletions (indels) with variant- and gene-centric information relevant to cancer researchers. This information is drawn from 14 different publicly available resources that have been pooled and indexed, and we provide an extensible framework to add additional data sources. Annotations linked to variants range from basic information, such as gene names and functional classification (e.g. missense), to cancer-specific data from resources such as the Catalogue of Somatic Mutations in Cancer (COSMIC), the Cancer Gene Census, and The Cancer Genome Atlas (TCGA). For local use, Oncotator is freely available as a python module hosted on Github (https://github.com/broadinstitute/oncotator). Furthermore, Oncotator is also available as a web service and web application at http://www.broadinstitute.org/oncotator/.
                Bookmark

                Author and article information

                Contributors
                kpwhite@uchicago.edu
                dhuo@health.bsd.uchicago.edu
                folopade@medicine.bsd.uchicago.edu
                jordi.barretina@gmail.com
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                16 October 2018
                16 October 2018
                2018
                : 9
                : 4181
                Affiliations
                [1 ]ISNI 0000 0004 1936 7822, GRID grid.170205.1, Institute for Genomics and Systems Biology, , University of Chicago, ; Chicago, IL 60637 USA
                [2 ]ISNI 0000 0004 0439 2056, GRID grid.418424.f, Novartis Institutes for BioMedical Research, ; Cambridge, MA 02139 USA
                [3 ]ISNI 0000 0004 1936 7822, GRID grid.170205.1, Center for Clinical Cancer Genetics & Global Health, Department of Medicine, , University of Chicago, ; Chicago, IL 60637 USA
                [4 ]ISNI 0000 0004 0481 2583, GRID grid.411278.9, Department of Pathology and Forensic Medicine, , Lagos State University Teaching Hospital, ; Ikeja, Lagos Nigeria
                [5 ]ISNI 0000 0004 1794 5983, GRID grid.9582.6, Department of Pathology, , University of Ibadan, ; Ibadan, Oyo Nigeria
                [6 ]ISNI 0000 0001 2256 9319, GRID grid.11135.37, Department of Epidemiology and Biostatistics, School of Public Health, , Peking University Health Science Center, ; Beijing, 100191 China
                [7 ]ISNI 0000 0004 1794 5983, GRID grid.9582.6, Institute for Advanced Medical Research and Training, College of Medicine, , University of Ibadan, ; Ibadan, Oyo Nigeria
                [8 ]ISNI 0000 0004 1794 5983, GRID grid.9582.6, Department of Surgery, , University of Ibadan, ; Ibadan, Oyo Nigeria
                [9 ]ISNI 0000 0004 0481 2583, GRID grid.411278.9, Department of Surgery, , Lagos State University Teaching Hospital, ; Ikeja, Lagos Nigeria
                [10 ]ISNI 0000 0004 1794 5983, GRID grid.9582.6, Department of Pharmaceutical Chemistry, , University of Ibadan, ; Ibadan, Oyo Nigeria
                [11 ]ISNI 0000 0001 0725 8811, GRID grid.411276.7, Oncology Unit, Department of Radiology, , Lagos State University, ; Ikeja, Lagos Nigeria
                [12 ]ISNI 0000 0004 1936 7822, GRID grid.170205.1, Department of Public Health Sciences, , University of Chicago, ; Chicago, IL 60637 USA
                [13 ]ISNI 0000 0004 1795 1830, GRID grid.451388.3, The Francis Crick Institute, ; 1 Midland Road, London, NW1 1AT UK
                [14 ]ISNI 0000 0001 0668 7884, GRID grid.5596.f, Department of Human Genetics, , University of Leuven, ; Oude Markt 13, Leuven, 3000 Belgium
                [15 ]ISNI 0000 0004 1794 5983, GRID grid.9582.6, Centre for Population and Reproductive Health, College of Medicine, , University of Ibadan, ; Ibadan, Oyo Nigeria
                [16 ]ISNI 0000 0001 2180 6431, GRID grid.4280.e, Present Address: Cancer Science Institute of Singapore, , National University of Singapore, ; 14 Medical Drive, Singapore, 117599 Singapore
                [17 ]GRID grid.429182.4, Present Address: Girona Biomedical Research Institute (IDIBGI), ; Girona, 17007 Spain
                Author information
                http://orcid.org/0000-0002-4759-8332
                http://orcid.org/0000-0001-6597-7072
                http://orcid.org/0000-0003-2674-8159
                http://orcid.org/0000-0002-0944-5618
                http://orcid.org/0000-0003-0292-1949
                http://orcid.org/0000-0002-9936-1599
                http://orcid.org/0000-0002-3478-4080
                Article
                6616
                10.1038/s41467-018-06616-0
                6191428
                30327465
                dc4a6d75-65de-4993-8c61-f1931fe2f979
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 October 2017
                : 13 September 2018
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000054, U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI);
                Award ID: U01-CA161032
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Uncategorized
                Uncategorized

                Comments

                Comment on this article